BrainsWay Ltd. (BWAY)

NASDAQ: BWAY · IEX Real-Time Price · USD
1.72
-0.01 (-0.52%)
At close: Jun 2, 2023, 4:00 PM
1.75
+0.03 (1.69%)
After-hours: Jun 2, 2023, 4:00 PM EDT
-0.52%
Market Cap 29.48M
Revenue (ttm) 25.83M
Net Income (ttm) -13.79M
Shares Out 17.13M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,035
Open 1.76
Previous Close 1.73
Day's Range 1.71 - 1.76
52-Week Range 1.38 - 7.00
Beta 0.15
Analysts Strong Buy
Price Target 6.25 (+263.16%)
Earnings Date May 17, 2023

About BWAY

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company prim... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Apr 17, 2019
Employees 134
Stock Exchange NASDAQ
Ticker Symbol BWAY
Full Company Profile

Financial Performance

In 2022, Brainsway's revenue was $27.18 million, a decrease of -8.36% compared to the previous year's $29.66 million. Losses were -$13.35 million, 106.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price forecast is $6.25, which is an increase of 263.16% from the latest price.

Price Target
$6.25
(263.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BrainsWay Announces Appointment of Ido Marom as CFO

BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

1 week ago - GlobeNewsWire

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain d...

2 weeks ago - GlobeNewsWire

BrainsWay Launches Investigator Initiated Study (IIS) Program

Application Period Open for Data Collaboration and Equipment Loan Initiatives Application Period Open for Data Collaboration and Equipment Loan Initiatives

2 weeks ago - GlobeNewsWire
}

BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023

BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

1 month ago - GlobeNewsWire

BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression

Real-World Evidence Demonstrates the Highest Response and  Remission Rates Observed to Date for Deep

2 months ago - GlobeNewsWire

BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain...

2 months ago - GlobeNewsWire

BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023

BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...

3 months ago - GlobeNewsWire

BrainsWay Announces Appointment of Hadar Levy as CEO

BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

3 months ago - GlobeNewsWire
}

BrainsWay Announces Appointment of Ami Boehm as New Chairman

David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serve as Board Director David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serv...

3 months ago - GlobeNewsWire

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

5 months ago - GlobeNewsWire

BrainsWay Resolves Neuronetics Litigation

BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...

5 months ago - GlobeNewsWire

BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom

BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...

6 months ago - GlobeNewsWire

BrainsWay Reports Open Market Stock Purchases by Two Board Members

BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...

6 months ago - GlobeNewsWire
}

BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights

Conference call to be held today, November 16, 2022, at 8:30 AM ET Conference call to be held today, November 16, 2022, at 8:30 AM ET

7 months ago - GlobeNewsWire

BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™

Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients

7 months ago - GlobeNewsWire

BrainsWay to Report Third Quarter Financial Results on November 16, 2022

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

7 months ago - GlobeNewsWire

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years

7 months ago - GlobeNewsWire

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and noninvasive treatment for brain ...

9 months ago - GlobeNewsWire

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™

Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsi...

9 months ago - GlobeNewsWire

BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, Aug. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced and non-invasive treatment for brain...

9 months ago - GlobeNewsWire

BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression

Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company's 9th FDA Clearance Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company's 9th FDA Cleara...

9 months ago - GlobeNewsWire

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 14% Year-over-Year in Q2 2022

10 months ago - GlobeNewsWire

BrainsWay to Report Second Quarter Financial Results on August 10, 2022

BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

11 months ago - GlobeNewsWire

BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

The Company's Groundbreaking Deep TMS™ Treatment is Included in Israel's Health Basket of Essential Medical Services The Company's Groundbreaking Deep TMS™ Treatment is Included in Israel's Health Bas...

1 year ago - GlobeNewsWire

BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference

BURLINGTON, Mass. and JERUSALEM, June 22, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

1 year ago - GlobeNewsWire